Dialysis world news

3 Stocks Pushing The Health Services Industry Lower - TheStreet.com

3 Stocks Pushing The Health Services Industry Lower
KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co. KGaA has a market cap of $25.5 ...

and more »


Today's Roof Leaker Stock Is DaVita HealthCare Partners (DVA) - TheStreet.com
DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. DVA has a PE ratio of 39.
DaVita HealthCare Partners Director Sells $322757.34 in Stock (DVA) Dakota Financial News
Inside Trading: Carol Davidson Unloaded 4038 Shares of DaVita HealthCare ... OctaFinance.com
Davita Healthcare Partners Inc. (DVA) Files Form 4 Insider Selling : Carol


Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Winifred ... - American Trade Journal

Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Winifred L Swan , SVP and General Counsel of Nxstage Medical, Inc. sold 2,500 shares on Aug 14, 2015. The Insider selling transaction was disclosed on Aug 17, 2015 to the Securities and Exchange Commission. The shares were sold at $18.14 per share for a total value of $45,350.00.

The company shares have rallied 37.01% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $15.12 and the 200 day moving average is recorded at $16.65. S&P 500 has rallied 6.63% during the last 52-weeks. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. Wall Street Brokerage Firms have recommended on the company shares. 5 analysts have rated the shares as a strong buy. The Company shares has received a rating of Buy from 1 Wall Street Analysts. 1 analysts have rated Hold. A Sell call was given by 1 analyst. NxStage Medical, Inc. (NASDAQ:NXTM) should head towards $21 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $15 per share. The higher price estimate target is at $24 according to the Analysts. Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Tuesday session in red amid volatile trading. The shares closed down 0.17 points or 0.93% at $18.19 with 399,924 shares getting traded. Post opening the session at $18.28, the shares hit an intraday low of $18.09 and an intraday high of $18.47 and the price vacillated in this range throughout the day. The company has a market cap of $1,154 million and the number of outstanding shares has been calculated to be 63,448,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.


Manitoba to help home dialysis patients pay utility costs - CBC.ca

Manitoba's health minister says the province will reimburse home dialysis patients for their extra utility costs.

Sharon Blady says water and electricity bills can add up for patients who are treated at home.

Repayment will be based on utility use during scheduled dialysis and on the type of machine used.

She says home dialysis is still almost nearly 50 per cent less costly than in hospitals.

That's because it reduces the need for hospital space and requires fewer health-care workers.

The reimbursements will be administered by the Manitoba branch of the Kidney Foundation of Canada.

"We hope these new supports will encourage more patients to undergo hemodialysis treatment in the comfort of their own home and enjoy a better quality of life," Blady said in a release Thursday.


Parker Receives Award from American Society of Nephrology - UB School of Medicine and Biomedical Sciences News

Parker Receives Award from American Society of Nephrology
UB School of Medicine and Biomedical Sciences News
Mark D. Parker, PhD, received a grant from the American Society of Nephrology Foundation for Kidney Research to help further his research on acidosis. Parker Receives Award from American Society of Nephrology. Published August 20, 2015.


<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 4 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.